allogeneic Power3 knock-out CD19 CAR-T
/ EdiGene, Chinese PLA General Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 02, 2024
TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital | Trial completion date: Jul 2027 ➔ Feb 2028 | Initiation date: Jul 2024 ➔ Feb 2025 | Trial primary completion date: Jul 2026 ➔ Feb 2027
CAR T-Cell Therapy • Trial completion date • Trial initiation date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology
July 01, 2024
TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital
CAR T-Cell Therapy • New P1/2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology
1 to 2
Of
2
Go to page
1